NDA 021844 · Leo Pharma As
Desonate
Desonide · Topical
DiscontinuedLast checked: Nov 20, 2026Latest source record: Mar 14, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Oct 20, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
4 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- DESONATE · DESONIDE 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GEL, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Desonide" as an intervention, any sponsor and status, largest first.
- Emollients in the Management of Atopic DermatitisPivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT01779258 · 347 participants · Start Feb 2013 · Primary completion Feb 2014
Drug: glycerol, paraffin (liquid and white soft); Locatop@ and 1 more · For: Atopic Dermatitis
Sites: Tallinn, Estonia; Tartu, Estonia; Bordeaux, France · 15 sites in all
- Efficacy Emollient on Xerosis in Children With Atopic DermatitisPivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT01467362 · 251 participants · Start Nov 2011 · Primary completion May 2012
Drug: V0034CR01B; Vehicle cream and 1 more · For: Atopic Dermatitis
Sites: Tallinn, Estonia; Tartu, Estonia; Bordeaux, France · 25 sites in all
- Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic DermatitisPivotal-lookingCompleted
Promius Pharma, LLCIndustry
NCT00828412 · 100 participants · Start Mar 2009 · Primary completion Aug 2009
Drug: Desonide Cream 0.05% · For: Atopic Dermatitis
Sites: Denver, Colorado; Chicago, Illinois; Winston-Salem, North Carolina · 5 sites in all
- 8-Week Atopic Dermatitis (AD) Treatment StudyPivotal-lookingCompleted
Procter and GambleIndustry
NCT03386032 · 65 participants · Start Nov 27, 2017 · Primary completion Aug 18, 2018
Drug: Investigational OTC Cream; 0.05% Desonide · For: Atopic Dermatitis Eczema
Sites: Raleigh, North Carolina; Chattanooga, Tennessee
Procter & Gamble BeautyIndustry
NCT02732314 · 53 participants · Start Mar 2016 · Primary completion Jun 2016
Drug: Investigational OTC Cream; 0.05% Desonide Cream · For: Dermatitis, Atopic; Eczema
Sites: Raleigh, North Carolina
- URGO FilmoCream Eczema + Dermocorticoids in Atopic DermatitisNot yet recruiting
CEN BiotechIndustry
NCT07295678 · 44 participants (planned) · Start Jan 5, 2026 · Primary completion Jul 30, 2026
Drug: Treatment period with dermocorticoid alone; Follow-up period after dermocorticoid treatment alone · For: Atopic Dermatitis
Sites: Gdansk, Poland; Malbork, Poland
- Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic DermatitisPivotal-lookingStatus unknown
NeoStrata Company, Inc.Industry
NCT02286700 · 42 participants (planned) · Start Nov 2014 · Primary completion Feb 2015
Drug: Desonide Cream · For: Dermatitis, Atopic; Eczema
Sites: Boston, Massachusetts
- Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic DermatitisCompleted
Wake Forest UniversityAcademic, hospital or other
NCT00690833 · 41 participants · Start Aug 2007 · Primary completion Dec 2007
Drug: topical desonide hydrogel 0.05% · For: Atopic Dermatitis
Sites: Winston-Salem, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Axillary Hyperpigmentation Treatment: A Systematic Review of the Literature.
Vahabi SM, Sajjadi S, Kalantari Y, et al. · J Cosmet Dermatol 2025 · Systematic Review
- Desonide foam 0.05%: safety in children as young as 3 months.
Hebert AA · J Am Acad Dermatol 2008 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis.
Eichenfield LF, Basu S, Calvarese B, et al. · Pediatr Dermatol 2007 · Clinical Trial, Multicenter Study
- Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis.
Lucky AW, Grote GD, Williams JL, et al. · Cutis 1997 · Clinical Trial, Comparative Study
- Clinical efficacy of mucopolysaccharide polysulfate ointment combined with desonide ointment in treatment of infantile eczema.
Dang Y, Yang L, Jia Y, et al. · Pak J Pharm Sci 2019 · Randomized Controlled Trial
- Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis.
Swinyer LJ, Decroix J, Langner A, et al. · Cutis 2007 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Leo Pharma As
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.